Articles  |   February 2020
Anesthetic Considerations for Bariatric Endoscopy, Part 2: FDA-approved Endoscopic Bariatric and Metabolic Therapies and Anesthetic Considerations
Article Information
Gastrointestinal and Hepatic Systems / Respiratory System / Technology / Equipment / Monitoring / Advocacy and Legislative Issues / Articles
Articles   |   February 2020
Anesthetic Considerations for Bariatric Endoscopy, Part 2: FDA-approved Endoscopic Bariatric and Metabolic Therapies and Anesthetic Considerations
ASA Monitor 2 2020, Vol.84, 56-61.
ASA Monitor 2 2020, Vol.84, 56-61.
Intragastric balloons were developed as a restrictive endoscopic procedure for obesity treatment, with the intent of filling the stomach to induce early satiety. As a primary treatment for Class II/III obesity (BMI >35 kg/m2), patients should achieve a mean minimum threshold of 25 percent excess weight loss as measured at 12 months.2,11  Although there are ongoing trials for newer devices, there are currently four FDA-approved intragastric balloon devices: the ReShape Dual Integrated Balloon System (Apollo Endosurgery, Austin, TX), the Orbera Intragastric Balloon System (Apollo Endosurgery, Austin, TX), the Obalon Balloon System (Obalon Therapeutics, Carlsbad, CA) and the TransPyloric Shuttle (BAROnova, Inc., Goleta, CA). Of these four FDA-approved devices, only the Obalon Balloon system does not necessitate endoscopic placement. Apollo Endosurgery owns both the Reshape and the Orbera devices and is planning to phase out the Reshape device.
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×